Livestream: Digging Deeper into Abnormal Liver Test Results

Treatment for primary biliary cholangitis (PBC), a “common rare” chronic autoimmune disease of the intrahepatic bile ducts, is frequently hampered by missed or delayed diagnosis, as symptoms of PBC are often attributed to other conditions. This suboptimal recognition enables unchecked progression to end stage liver disease (ESLD), increasing patient mortality risk and negatively impacting quality of life. Clinical suspicion and investigation of key abnormal liver function tests represent a critical first step in optimized management. Similarly, identification of metabolic dysfunction-associated steatotic liver disease (MASLD) and its more severe form, metabolic dysfunction-associated steatohepatitis (MASH), requires practitioners to overcome clinical inertia and follow up on abnormal results from standard liver function tests to disrupt disease progression. Fortunately, recent FDA-approved agents and others in later stages of development are providing new and efficacious options for PBC and MASLD/MASH treatment. It is imperative that clinicians in collaboration with a multidisciplinary care team bridge diagnostic gaps and consider novel emerging therapies for patients with PBC and MASLD/MASH.

In this CME Outfitters livestream symposium, expert faculty will guide learners on identifying signs and symptoms of PBC, MASH, and MASLD, implementing evidence-based strategies for early and accurate diagnosis, implementing best practices for treatment, and applying multidisciplinary disease management to the care of patients.

At the conclusion of this activity, learners will be able to better:

• Identify signs and symptoms of PBC, MASH, and MASLD
• Implement evidence-based strategies for early and accurate diagnosis of PBC, MASLD, and MASH
• Assess new and emerging therapeutic pathways for PBC, MASLD, and MASH which impact treatment decision-making

This program is supported by independent educational grants from Gilead Sciences, Inc. and Ipsen Biopharmaceuticals, Inc.

Internists, physician associates (PAs), and nurse practitioners (NPs)

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CME/CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CME/CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. Relevant financial relationships exist between the following individuals and commercial interests:

Dr. Kowdley reports the following financial relationships:

Consultant: 89bio, Inc.; Arbormed Pharmaceuticals; Boehringer Ingelheim; CymaBay Therapeutics Inc.; Genfit; Gilead Sciences, Inc.; GSK; HighTide Therapeutics, Inc.; Inipharm; Intercept Pharmaceuticals, Inc.; Ipsen Pharma; Madrigal Pharmaceuticals; Mirum; NGM Biopharmaceuticals; Novo Nordisk; Orphalan; Pfizer Inc.; and Zydus Pharmaceuticals, Inc.

Grants: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Research Support: 89bio, Inc.; Akero Therapeutics, Inc.; AstraZeneca; Boston Pharmaceuticals; Boehringer Ingelheim; Corcept Therapeutics, Inc.; Gilead Sciences, Inc.; GSK; Hanmi Pharmaceutical; Intercept Pharmaceuticals, Inc.; Inventiva; Janssen Pharmaceuticals, Inc.; Madrigal Pharmaceuticals; Mirum, NGM Biopharmaceuticals; Novo Nordisk; Pfizer Inc.; Pliant Therapeutics, Inc.; Terns Pharmaceuticals, Inc.; Viking Therapeutics; and Zydus Pharmaceuticals, Inc.

Speakers Bureau: AbbVie Inc.; Gilead Sciences, Inc.; Intercept Pharmaceuticals, Inc.; and Ipsen Pharma

Other financial or material support: Royalties: UpToDate

Ms. Legaspi reports no financial relationships to disclose.

Dr. Tincopa reports the following financial relationships:

Consultant: AbbVie Inc. and Optum, Inc.

The following individuals have no financial relationships to disclose:

Rebecca Vargas-Jackson, MD (Peer Reviewer)
Amanda K. Smith, PA-C (Peer Reviewer)
Keshia Pitt, PhD (Planning Committee)
Warren Beckman (Planning Committee)
Scott J. Hershman, MD, FACEHP, CHCP (Planning Committee)
Sandra Caballero, PharmD (Planning Committee)
Sharon Tordoff (Planning Committee)
Maria Morias (Patient/Patient Advocate)

*All identified conflicts of interest have been mitigated.

Unlabeled Use Disclosure
Faculty of this CME/CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices. CME Outfitters, LLC, the faculty, planners, and reviewers do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.

Post-tests, credit request forms, and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately (0% pass rate required). This website supports all browsers except Internet Explorer for Mac.

Call us at 877.CME.PROS (877.263.7767).

MMS-151-040225-90